Rivaroxaban Plasma Levels and Levetiracetam
Authors: Marc A. Brouwer, Stijn P.G. van Vugt, Jeroen Jaspers Focks, Sander A.J. Damen, Freek W.A. Verheugt
Journal: Annals of Internal Medicine (2020)

Letters3 November 2020Rivaroxaban Plasma Levels and LevetiracetamMarc A. Brouwer, MD, PhD, Stijn P.G. van Vugt, MD, Jeroen Jaspers Focks, MD, PhD, Sander A.J. Damen, MD, and Freek W.A. Verheugt, MD, PhDMarc A. Brouwer, MD, PhDRadboud University Medical Center, Nijmegen, the Netherlands (M.A.B., S.P.V., J.J.F., S.A.D.)Search for more papers by this author, Stijn P.G. van Vugt, MDRadboud University Medical Center, Nijmegen, the Netherlands (M.A.B., S.P.V., J.J.F., S.A.D.)Search for more papers by this author, Jeroen Jaspers Focks, MD, PhDRadboud University Medical Center, Nijmegen, the Netherlands (M.A.B., S.P.V., J.J.F., S.A.D.)Search for more papers by this author, Sander A.J. Damen, MDRadboud University Medical Center, Nijmegen, the Netherlands (M.A.B., S.P.V., J.J.F., S.A.D.)Search for more papers by this author, and Freek W.A. Verheugt, MD, PhDOnze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands (F.W.V.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-1063 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Paciullo and colleagues' case report (1) with interest. Especially during the coronavirus disease 2019 (COVID-19) pandemic, this information is crucial for daily clinical decision making. Thrombotic complications are common, and many patients have an indication for anticoagulant therapy (2). In the acute phase, treatment is often confined to unfractionated or low-molecular-weight heparin; however, physicians may opt to prescribe non–vitamin K oral anticoagulants (NOACs) after discharge.In general, NOACs have been proved to be a safe and effective alternative to vitamin K antagonists, without need for monitoring (3). However, the situation in Paciullo and colleagues' case ...References1. Paciullo F, Costa C, Gresele P. Rivaroxaban plasma levels and levetiracetam: a case report [Letter]. Ann Intern Med. 2020;173:71-2 LinkGoogle Scholar2. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19 [Letter]. N Engl J Med. 2020;382:e38. [PMID: 32268022] CrossrefMedlineGoogle Scholar3. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-62. [PMID: 24315724] CrossrefMedlineGoogle Scholar4. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707-24. [PMID: 15301575] CrossrefMedlineGoogle Scholar5. Jeevaratnam K. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety [Letter]. Eur Heart J Cardiovasc Pharmacother. 2020;6:256-7. [PMID: 32347923] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Radboud University Medical Center, Nijmegen, the Netherlands (M.A.B., S.P.V., J.J.F., S.A.D.)Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands (F.W.V.)Note: Drs. Brouwer and Jaspers Focks have received consulting fees/honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, and Daiichi Sankyo. Dr. Verheugt has received educational and research grants from Bayer Healthcare and Boehringer Ingelheim, as well as honoraria for consultancies/presentations from Daiichi Sankyo, Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, and Bayer Healthcare.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1063. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRivaroxaban Plasma Levels and Levetiracetam: A Case Report Francesco Paciullo , Cinzia Costa , and Paolo Gresele Rivaroxaban Plasma Levels and Levetiracetam Maja Hellfritzsch , Jakob Christensen , and Lars Peter Nielsen Rivaroxaban Plasma Levels and Levetiracetam Vineet Punia Rivaroxaban Plasma Levels and Levetiracetam Francesco Paciullo , Cinzia Costa , and Paolo Gresele Metrics 3 November 2020Volume 173, Issue 9Page: 770-771KeywordsAnticoagulant therapyBlood plasmaCOVID-19ChloroquineDisclosureDrugsHalf lifeHealth careResearch grantsVitamin K ePublished: 3 November 2020 Issue Published: 3 November 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...